Vizient announces Novaplus enhanced supply agreement with Pfizer for 7 additional essential medications

December 3, 2020  –  Vizient, Inc. (Irving, TX) has signed an agreement with Pfizer Inc. to add seven essential medications to its Novaplus Enhanced Supply program, part of Vizient’s private label pharmacy solution.

The agreement brings an additional 10 million total units of product across the seven medications, including four that have a greater impact on pediatric patient populations.

Under the Novaplus Enhanced Supply program, suppliers commit to manufacturing additional supply of essential medications which, if not available, would prove the greatest threat to hospitals’ ability to provide immediate and high-quality patient care. Novaplus Enhanced Supply program suppliers agree to maintain additional, onshore inventory based on the historical usage of Vizient members. In June, Pfizer added six medications to the program.

One of the medications, midazolam hydrochloride is used in supportive care of patients with COVID-19 and four of Pfizer’s other latest additions have a greater impact on the pediatric patient population because there are fewer alternative medications approved to treat this population. Two are categorized acute, lifesaving — and five are categorized as high impact as part of Vizient’s essential medications list.

Acute, lifesaving:

  • Methotrexate Injection, USP
  • Phytonadione Injectable Emulsion, USP *

High impact:

  • Ceftriaxone for Injection, USP
  • Labetalol Hydrochloride Injection, USP
  • Midazolam Injection, USP C-IV *
  • Milrinone Lactate Injection *
  • Vancomycin Hydrochloride for Injection, USP *

Learn More

*Greater pediatric patient population impact.